Bile duct complications of hepatic arterial infusion chemotherapy evaluated by helical CT

Phongkitkarun, Sith; Kobayashi, Satoshi; Varavithya, Vithya; Huang, Xuelin; Curley, Steven A.; Charnsangavej, C.

doi:10.1016/j.crad.2005.01.006

Cited by 29 publications

(11 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[1][2][3][4]6,7,16,17 This wide range in the reported incidence may be explained by differences in the diagnostic criteria for CISC, its detection rate, and varying HAIC regimens among institutions. Chemotherapyinduced sclerosing cholangitis is sometimes refractory to treatment and potentially life-threatening.…”

Section: Discussionmentioning

confidence: 83%

See 1 more Smart Citation

Chemotherapy-induced sclerosing cholangitis as a rare indication for resection: Report of a case

et al. 2009

View full text Add to dashboard Cite

Bile duct stricture due to chemotherapy-induced sclerosing cholangitis (CISC) is a potentially fatal complication of hepatic arterial infusion chemotherapy (HAIC). It is managed primarily with medical treatment and biliary stenting. We report a rare case of a CISC-related biliary stricture requiring resection. The patient had been receiving adjuvant HAIC for 11 months after a curative liver resection for hepatocellular carcinoma, when clinically overt cholangitis developed. Radiologic and biopsy findings suggested a CISC-related biliary stricture limited to the common hepatic duct. We discontinued HAIC and started corticosteroid treatment, which finally became ineffective. Endoscopic biliary stenting was impossible because of her severe biliary sclerosis, necessitating resection of the stricture, which was confirmed histologically to be secondary sclerosing cholangitis. The patient has shown no signs of recurrent cholangitis for 12 postoperative months since her operation. Thus, resection could be a treatment option for a CISC-related biliary stricture in selected patients.

show abstract

Section: Discussionmentioning

confidence: 83%

“…Serum ALP is a useful marker, which may be elevated from the early stage of CISC. 17 Thin-section helical CT may also be useful for the early diagnosis of CISC. According to one study, CT fi ndings and grades correlated well with an abnormal elevation of serum ALP and bilirubin.…”

Section: Discussionmentioning

confidence: 99%

Chemotherapy-induced sclerosing cholangitis as a rare indication for resection: Report of a case

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Cholestatic DILI from development of secondary sclerosing cholangitis has been reported with chemotherapeutic agents, (53,54) and cases have been reported with ketamine and methimazole. (55)(56)(57) Secondary sclerosing cholangitis associated with the use of docetaxel was recently reported.…”

Section: Secondary Sclerosing Cholangitismentioning

confidence: 99%

Drug-Induced Cholestasis

Bjõrnsson

2014

Clinical Gastroenterology

View full text Add to dashboard Cite

Cholestatic drug-induced liver injury (DILI) can be a diagnostic challenge due to a large differential diagnosis, variability in clinical presentation, and lack of serologic biomarkers associated with this condition. The clinical presentation of druginduced cholestasis includes bland cholestasis, cholestatic hepatitis, secondary sclerosing cholangitis, and vanishing bile duct syndrome. The associate mortality of cholestatic DILI can be as high as 10%, and thus prompt recognition and removal of the offending agent is of critical importance. Several risk factors have been identified for drug-induced cholestasis, including older age, genetic determinants, and properties of certain medications. Antibiotics, particularly amoxicillin/clavulanate, remain the predominant cause of cholestatic DILI, although a variety of other medications associated with this condition have been identified. In this review, we summarize the presentation, clinical approach, risk factors, implicated medications, and management of drug-induced cholestatic liver injury. (Hepatology Communications 2017;1:726-735)

show abstract

“…Hepatic artery infusion of floxuridine for treatment of hepatic metastases from colorectal carcinoma has been associated with a sclerosing cholangitis-like lesion resulting in hepatic failure. The etiology of these changes may be ischemic rather than toxic, as the bile ducts are supplied by the hepatic artery 50,51 Although treatment regimens now attempt to minimize the risk of this complication, the majority of patients receiving this therapy develop bile duct abnormalities on hepatic imaging. 51 Langerhans' cell histiocytosis may present with isolated hepatic involvement or with involvement of other organ systems, most commonly lymph node and skin.…”

Section: Secondary Sclerosing Cholangiopathiesmentioning

confidence: 99%

“…The etiology of these changes may be ischemic rather than toxic, as the bile ducts are supplied by the hepatic artery 50,51 Although treatment regimens now attempt to minimize the risk of this complication, the majority of patients receiving this therapy develop bile duct abnormalities on hepatic imaging. 51 Langerhans' cell histiocytosis may present with isolated hepatic involvement or with involvement of other organ systems, most commonly lymph node and skin. In one study, seven of nine cases demonstrated injury to small and medium intrahepatic bile ducts by infiltrating Langerhans' cells.…”

Section: Secondary Sclerosing Cholangiopathiesmentioning

confidence: 99%